2018 was a strong year for our Tiara and Reducer product platforms. Both have achieved significant therapy development milestones, putting Neovasc on a stronger foundation from which to continue advancing these products commercially. We also have a clear value creation strategy for patients, employees, and investors. All of this is really good news for our outlook.
Investor Overview
Latest News
Neovasc Announces US $12.6 Million Registered Direct Offering Priced At-The-Market
> read full release
Presentations and Events
Second Quarter 2020 Earnings Call, August 6, 4:30p.m ET
replay >
REDUCER - I interim results presented by
Pr. Verheye at PCR e-course 2020
view here >
Neovasc Presentation - June 2020
.pptx format (excel) > .pdf format (acrobat) >
Financial Report Archives
2020 Financial Reports
News Release Archives
2020 News Releases
Share Information
Auditor
Grant Thornton LLP, Vancouver, BC
Legal Counsel
Blakes LLP, Vancouver, BC
Transfer Agent
Computershare, Vancouver, BC
Investor Relations
Chris Clark, Chief Financial Officer
investors@neovasc.com
To automatically receive news updates